Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

An Open-label, Randomized, Active-controlled Study to Compare the Effect of 16 Weeks Treatment With Vildagliptin to Pioglitazone as add-on Therapy to Metformin in Type 2 Diabetic Patients Inadequately Controlled With Metformin Monotherapy

The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: vildagliptin; Drug: Pioglitazone

Detailed Description

Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that result from pancreatic islet dysfunction. Presently available oral antihypoglycemic drug improves glycemic control over the short term, none has been shown to stop the progressive decline in beta cell function which contributes to the deterioration of glycemic control over time.

Pathophysiology of T2DM is known as tissue resistance for insulin and progressive beta cell failure. Which one attributes first is unclear, but non-obese T2DM patients often show normal fasting plasma glucose (FPG) but postprandial plasma glucose (PPG) level is high and reduced or lacking normal compensatory insulin secretion. In Korea, more than 80% of T2DM are non-obese type (BMI >= 27 ) and it was observed that basal insulin level and compensatory insulin secretion reaction were reduced in normal healthy population. Based on that, metformin is an established first line treatment for type 2 diabetes, acting primarily to enhance hepatic and peripheral insulin sensitivity. However, it has become increasingly apparent that many patients require a combination of agents to attain optimal glycemic control.

Better understanding of incretin effect on the pathophysiology of T2DM has recently led to development of new oral hypoglycemic agents. Vildagliptin is a potent and highly selective dipeptidyl peptidase (DPP)-IV inhibitor that improves islet function by increasing pancreatic alpha and beta cell responsiveness to glucose. Studies in patients with T2DM have shown that vildagliptin significantly reduced HbA1c and FPG level from baseline and did not induce weight gain and the incidence of hypoglycemia was low. In addition, studies in rodents support an effort of vildagliptin on beta cell remodeling.

The thiazolidinediones are effective in reducing HbA1C in obese T2DM patients and it is known that only thiazolidinedione can delay the beta cell failure . But recently, thiazolidinediones were found to be associated with a decrease in bone mineral density and to raise the risk of myocardial infarct and cardiovascular related mortality. Thus, there is a need for new classes of blood glucose lowering drug which has the potential to delay or prevent the progression of T2DM.

• Study Type: Interventional
• Enrollment (Actual): 287
• Phase: Phase 4

Contacts and Locations

Study Locations

• Korea, Republic of
  • Busan, Korea, Republic of
    • Kosin University Hospital
  • Busan, Korea, Republic of
    • Pusan National University Hospital
  • Busan, Korea, Republic of
    • Busan Saint Mary's Medical Center
  • Busan, Korea, Republic of
    • Dong-AUniversity Medical Center
  • Busan, Korea, Republic of
    • Inje University Baik Hospital
  • Changwon, Korea, Republic of
    • Changwon Fatima Hospital
  • Daegu, Korea, Republic of
    • Daegu Catholic University Medical Center
  • Daegu, Korea, Republic of
    • Keimyung University Dongsan Medical Center
  • Daegu, Korea, Republic of
    • Kyungbuk National Universtiy Hospital
  • Gwangju, Korea, Republic of
    • Chonnam National University Hospital
  • Gwangju, Korea, Republic of
    • Chosun University Hospital
  • Jeonju, Korea, Republic of
    • Chonbuk National University Hospital
  • Jinju, Korea, Republic of
    • Gyeongsang National University Hospital
  • Masan, Korea, Republic of
    • Masan Samsung Medical Center
  • Ulsan, Korea, Republic of
    • Ulsan University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age in the range of 18 to 80 years
2. HbA1c 7 to 11%
3. FPG < 270 mg/dL (15 mmol/L);
4. Agreement to maintain prior diet & exercise
5. Written informed consent to participate in the study

Exclusion criteria:

1. Type 1 diabetes or Any kind of secondary diabetes
2. Pregnant or lactating women
3. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.
4. Significant diabetes complications e.g., symptomatic autonomic neuropathy or gastroparesis

5. Previous history of severe cardiovascular disease such as

   1. Torsades de Pointes, sustained and clinically relevant ventricular tachycardia, or ventricular fibrillation
   2. Percutaneous coronary intervention within the past 3 months

6. Any of the following within the past 6 months

   1. Myocardial infarction (MI) (if the visit 1 ECG reveals patterns consistent with an MI and the date of the event cannot be determined, then the patient can enter the study at the discretion of the investigator and the sponsor)
   2. Coronary artery bypass surgery
   3. Unstable angina
   4. Stroke
7. Congestive heart failure (NYHA class I to IV)
8. Liver disease such as cirrhosis or chronic active hepatitis
9. Known sensitivity to pioglitazone, rosiglitazone, or similar drugs
10. Chronic insulin treatment (> 4 weeks of treatment in the absence of an intercurrent illness) within the past 6 months
11. Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1

12. Any of the following laboratory abnormalities

    1. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than 2.5 times the upper limit of the normal range at visit 1
    2. Direct bilirubin greater than 1.3 times the upper limit of the normal range at visit 1
    3. Serum creatinine levels > 2.5 mg/dL (220 μmol/L) at visit 1
    4. Clinically significant thyroid-stimulating hormone (TSH) outside normal range at visit 1

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: vildagliptin; vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy	Drug: vildagliptin; vildagliptin 50mg bid for 16 weeks; Other Names: Galvus
Active Comparator: pioglitazone; Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy	Drug: Pioglitazone; Pioglitazone 15mg bid for 16 weeks; Other Names: Actos

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Non-inferiority of HbA1C Change From Baseline in Vildagliptin + Metformin Group Compared With Pioglitazone + Metformin Group	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the Mean Changes of FPG and PPG From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups	After 16 weeks, to assess the effect of vildagliptin compared with the effect of pioglitazone on Fasting Plasma Glucose (FPG); After 16 weeks, to assess the effect of vildagliptin compared with the effect of pioglitazone on Postprandial Glucose (PPG)	16 weeks , visit 5
the Mean Changes of Lipid Profiles From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups	The Mean Changes of Lipid Profiles(Triglyceride, Total cholesterol, LDL, HDL, Non-HDL cholesterol) From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups after 16weeks	16 weeks, visit 5
the Mean Changes of Body Weight From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups		16 weeks, visit 5
the Mean Changes of Insulin, C-peptide, HOMA-IR, HOMA-beta From Baseline Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups		16 weeks, visit 5

Other Outcome Measures

Outcome Measure	Time Frame
the Numbers of Participants With Adverse Events Between Vildagliptin + Metformin and Pioglitazone + Metformin Groups	16 weeks, visit 3,4,5

Collaborators and Investigators

• Sponsor: Pusan National University Hospital
• Investigators: Principal Investigator: In Ju Kim, MD, Pusan National University Hospital

Study record dates

Study Major Dates

• Study Start: December 1, 2009
• Primary Completion (Actual): March 1, 2013
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: June 3, 2013
• First Submitted That Met QC Criteria: June 18, 2013
• First Posted (Estimate): June 21, 2013

Study Record Updates

• Last Update Posted (Actual): March 21, 2019
• Last Update Submitted That Met QC Criteria: December 13, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Keywords: metformin; vildagliptin
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Dipeptidyl-Peptidase IV Inhibitors; Pioglitazone; Vildagliptin
• Other Study ID Numbers: CLAF237AKR05T